

Hyperbaric High Pressure Oxygen Therapy in Post-COVID Syndrome and ME/CFS

NCT06118138

Status RECRUITING
Sponsor Charite University, Berlin, Germany
Enrollment 60 participants

Key Eligibility Criteria

Inclusion (5)

- Participants between the ages of 18 and 65 years who have previously participated in the CFS_CARE study and have been diagnosed with ME/CFS
- ME/CFS diagnosis based on the Canadian Consensus Criteria (CCC), characterized by exercise intolerance and symptom worsening lasting for a minimum of 14 hours
- Disease severity determined by a Bell Score ranging from 30 to 70
- Plan to undergo 20 or 40 days of Hyperbaric Oxygen Therapy (HBOT)
- Consent provided by the patient

Exclusion (4)

- Unwillingness to consent to the storage of pseudonymized clinical data as a part of the study
- Pregnancy
- Presence of medical conditions that could potentially pose a risk during Hyperbaric Oxygen Therapy (HBOT) (e.g., heart failure, pulmonary disease, major depression, panic attacks)
- Acute infection (e.g., COVID, HIV, or hepatitis)

Locations (1 total)

Charité - Universitätsmedizin Berlin, Berlin, State of Berlin, Germany